WO2012024581A3 - Oxysterol compounds - Google Patents
Oxysterol compounds Download PDFInfo
- Publication number
- WO2012024581A3 WO2012024581A3 PCT/US2011/048414 US2011048414W WO2012024581A3 WO 2012024581 A3 WO2012024581 A3 WO 2012024581A3 US 2011048414 W US2011048414 W US 2011048414W WO 2012024581 A3 WO2012024581 A3 WO 2012024581A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- disclosed
- disorders
- oxysterol compounds
- oxysterol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Abstract
Compounds for use in the treatment of bone disorders, obesity, cardiovascular disorders and neurological disorders are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Z, E, R1 and q are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37554610P | 2010-08-20 | 2010-08-20 | |
US61/375,546 | 2010-08-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012024581A2 WO2012024581A2 (en) | 2012-02-23 |
WO2012024581A3 true WO2012024581A3 (en) | 2012-04-12 |
Family
ID=44583448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/048414 WO2012024581A2 (en) | 2010-08-20 | 2011-08-19 | Oxysterol compounds |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012024581A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005020928A2 (en) | 2003-08-29 | 2005-03-10 | The Regents Of The University Of California | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins |
WO2007098281A2 (en) | 2006-02-27 | 2007-08-30 | Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
EP2231164A1 (en) | 2007-12-03 | 2010-09-29 | The Regents of the University of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling |
RU2014149153A (en) * | 2012-05-07 | 2016-06-27 | Те Риджентс Оф Те Юниверсити Оф Калифорния | THE NEW ANALOGUE OF OXISTEROL, OXY149, INDUCES OSTEOGENESIS AND THE HEDGEHOG SIGNAL WAY AND INHIBITS LIPOGENESIS |
RU2632191C2 (en) * | 2012-05-07 | 2017-10-03 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Oxy133 OXYSTEROL ANALOGUE INDUCTS OSTEOGENESIS AND SIGNAL WAY HEDGEHOG AND INHIBITED LIPOGENESIS |
JP2016517888A (en) * | 2013-05-02 | 2016-06-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Oxysterol bone targeting drug for osteoselective bone formation |
EP3229809B1 (en) | 2014-12-09 | 2019-11-27 | Warsaw Orthopedic, Inc. | Compounds and methods involving sterols |
US10632230B2 (en) * | 2015-07-10 | 2020-04-28 | Warsaw Orthopedic, Inc. | Implants having a high drug load of an oxysterol and methods of use |
US9987289B2 (en) | 2015-07-10 | 2018-06-05 | Warsaw Orthopedic, Inc. | Slow release oxysterols and methods of use |
US9878070B2 (en) | 2015-06-17 | 2018-01-30 | Warsaw Orthopedic, Inc. | Malleable implants including an oxysterol and methods of use |
US9877836B2 (en) | 2015-07-10 | 2018-01-30 | Warsaw Orthopedic, Inc. | Compression resistant implants including an oxysterol and methods of use |
US9987290B2 (en) * | 2016-03-28 | 2018-06-05 | Warsaw Orthopedic, Inc. | Methods for the separation and detection of an oxysterol |
BR112019010798A2 (en) * | 2016-11-29 | 2019-10-01 | Enanta Pharm Inc | process for preparing sulfonylurea bile acid derivatives |
US11384114B2 (en) | 2016-12-09 | 2022-07-12 | Warsaw Orthopedic, Inc. | Polymorphic forms of an oxysterol and methods of making them |
EP3562827A1 (en) | 2016-12-30 | 2019-11-06 | Frequency Therapeutics, Inc. | 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
US10434106B2 (en) | 2017-05-19 | 2019-10-08 | Warsaw Orthopedic, Inc. | Oxysterol-statin compounds for bone growth |
US11464888B2 (en) * | 2017-06-12 | 2022-10-11 | Warsaw Orthopedic, Inc. | Moldable formulations containing an oxysterol in an acellular tissue matrix |
CN110551166B (en) * | 2018-05-31 | 2022-06-21 | 华东师范大学 | Cholic acid derivative and preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009073186A1 (en) * | 2007-12-03 | 2009-06-11 | The Regents Of The University Of California | Oxsterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling |
-
2011
- 2011-08-19 WO PCT/US2011/048414 patent/WO2012024581A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009073186A1 (en) * | 2007-12-03 | 2009-06-11 | The Regents Of The University Of California | Oxsterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling |
Also Published As
Publication number | Publication date |
---|---|
WO2012024581A2 (en) | 2012-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012024584A3 (en) | Oxysterol compounds | |
WO2012024581A3 (en) | Oxysterol compounds | |
WO2012016186A8 (en) | Macrocyclic kinase inhibitors and uses thereof | |
WO2011044501A3 (en) | Antibacterial aminoglycoside analogs | |
MX2014000341A (en) | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease. | |
WO2011044506A3 (en) | Sulphone compounds for use in the treatment of obesity | |
IN2014DN09805A (en) | ||
WO2012024583A3 (en) | Oxysterol compounds | |
WO2008097924A3 (en) | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders | |
WO2010030704A3 (en) | Antibacterial aminoglycoside analogs | |
WO2007135527A3 (en) | Benzimidazolyl compounds | |
UA109868C2 (en) | N -alkyltriazole compounds asr | |
MX2011012122A (en) | Thiophene derivatives. | |
WO2012154679A8 (en) | Tricyclic pyrazole sulfonamide compounds and methods of making and using same | |
WO2010132757A3 (en) | Antibacterial aminoglycoside analogs | |
WO2010037059A3 (en) | Heteroaryl antagonists of prostaglandin d2 receptors | |
IN2014DN09804A (en) | ||
WO2010132765A3 (en) | Antibacterial aminoglycoside analogs | |
WO2012048129A3 (en) | Inhibitors of polo-like kinase | |
WO2009108720A3 (en) | Antagonists of prostaglandin d2 receptors | |
WO2012054110A3 (en) | Compounds and methods for inhibiting phosphate transport | |
MX343135B (en) | Fumagillol type compounds and methods of making and using same. | |
WO2008000483A3 (en) | Phenol derivatives for the treatment of respiratory diseases | |
WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
EP3626253A3 (en) | Stable formulations of linaclotide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11752693 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11752693 Country of ref document: EP Kind code of ref document: A2 |